Base4 and Hitachi High-Tech Collaborate on Developing Novel Nanopore DNA-Sequencing System

Article

The core DNA-sequencing technology is based on the concept of passing a single strand of DNA through a nanometer-scale pore and reading out the sequence directly as it does so.

Base4 Innovation Ltd., a Cambridge-based DNA-sequencing company, and Hitachi High-Technologies Corporation, a technology company developing and manufacturing scientific and medical systems, announced that they have entered into an agreement to develop a long read-length, single-molecule, nanopore-based DNA-sequencing system based on Base4’s technology and Hitachi’s state-of-the-art instrumentation.

The core DNA-sequencing technology is based on the concept of passing a single strand of DNA through a nanometer-scale pore and reading out the sequence directly as it does so. A method was developed by Base4 to increase the signal from the single molecule as it passes through the pore by using laser light enhanced by gold structures. Minimal sample preparation is required and the signal can be read from unlabelled DNA.

The system offers easy analysis of genetic material. It will be able to directly read DNA modifications, such as methylation, which is relevant to the genes associated with cancer, as well as achieve long read lengths.

Recent Videos
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Adam Sherlock, CEO of Qinecsa Solutions
Related Content
© 2025 MJH Life Sciences

All rights reserved.